Advanced Oxidation Protein Product and Monocyte Chemoattractant Protein-1 in Periodontal Disease

Study Overview
=================
Brief Summary
-----------------
This study investigates the levels of advanced oxidation protein product and monocyte chemoattractant protein-1 in gingival crevicular fluid in periodontal disease and health. 25 participants with chronic periodontitis, 25 participants with gingivitis and 25 periodontally healthy subjects are included into this study. In each participant, four sites are identified for gingival crevicular fluid samples.

Detailed Description
-----------------
Oxidative stress is the disequilibrium between the formation of free radicals and antioxidant defense mechanisms via damaging cellular macromolecules (DNA, protein, lipid, etc..) which are susceptible to oxidative damage. Advanced oxidation protein product is identified as a new marker of protein oxidation. Monocyte chemoattractant protein-1 is a major chemoattractant for lymphocytes, monocytes and macrophages.

Official Title
-----------------
The Levels of Advanced Oxidation Protein Product and Monocyte Chemoattractant Protein-1 in Gingival Crevicular Fluid in Periodontal Disease and Health

Conditions
-----------------
Inflammation, Periodontal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of chronic periodontitis and gingivitis Exclusion Criteria: Systemic illnesses Any medications known to affect the periodontium Pregnancy and lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic periodontitis group<br>Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression | |
| Gingivitis group<br>Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at >50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis | |
| Periodontally healthy group<br>Subjects who have no sites with PD >3mm and CAL >0 mm, a BOP score of <15% at the examination and no alveolar bone loss. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Advanced oxidation protein product (nmol) |  | Before periodontal treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Monocyte chemoattractant protein-1(pg) |  | Before periodontal treatment | 
| The probing depth (mm), clinical attachment level (mm), plaque index scores (0-3) and gingival index scores (0-3) |  | Before periodontal treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced Oxidation Protein Products, Gingival crevicular fluid, Monocyte chemoattractant protein-1, Periodontal Disease